In March 2020, the Hospital of the University of Pennsylvania treated the Philadelphia region’s first COVID-19 patient. Since that time, Penn Medicine has made a singular, comprehensive and meticulous effort to make its facilities safe for its patients, faculty and staff, as well as the visiting public.
We are taking a number of measures to address the coronavirus-related concerns of physicians who are referring patients into the healthcare system and those who may be visiting our hospitals and associated facilities.
Hotline for COVID-19 Questions
Our toll-free hotline is open for your COVID-19 related patient care questions: 833-983-1350. (Select prompt 5 for provider line).
Heightened Safety for Appointment and Patient Procedures
Patient safety and access remain our top priorities. We have implemented contact-free check-in and check-out, updated clinical protocols, a universal masking policy, and socially distanced clinics and waiting rooms. All patients with in-office appointments are pre-screened by phone for symptoms consistent with COVID-19.
View about our safety protocols and visitor guidelines
Telemedicine Appointments
We now offer virtual visits for a variety of services, certain new patient appointments and follow-up care.
Learn more about telemedicine at Penn Medicine during the coronavirus
Lab Services
Prioritized orders for patients who require urgent laboratory testing are available from the Laboratory Patient Service Centers at Penn Medicine. For urgent testing guidelines, locations and hours, please visit our Outpatient Labs page.
Blood Bank, Transfusion Medicine and Coagulation Services
We have blood donation, transfusion and coagulation services available at specialized laboratories. Please call the following numbers to find out more.
Apheresis Services (blood bank and transfusion): 215-662-3441 or 215-662-3442
Comprehensive Hemostasis and Thrombosis Laboratory (coagulation services for bleeding and clotting disorders): 215-662-3447
COVID-19 Clinical Trials
Researchers are using their expertise to address the COVID-19 pandemic in a number of enrolling clinical trials at Penn Medicine and the Perelman School of Medicine.